Price to Earnings of Samsung Biologics

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

Price to Earnings analysis of Samsung Biologics


 Price 220,000.00  KRW
 Earnings per share -2,606.64  KRW
 Capitalization (mn) 3,056,823  KRW
 Net income (mn) -172,038  KRW
 P/E ratio -84.40
 Samsung Biologics dividend
 Samsung Biologics Price to book Value
 Samsung Biologics Price to Cash-Flow
 Samsung Biologics Return on Equity
 Samsung Biologics Financial analysis

Samsung Biologics is a Health Care industry firm, which concentrates their activity in the Pharmaceuticals and Biotechnology sector. Samsung Biologics headquarters are in Korea, where the firm is listed.

At the time of this analysis, Samsung Biologics stocks were trading at a price of 220,000.00 KRW after hiking a 25.70% last month.

According to the graph below, where Price to earnings comparison chart is displayed, Samsung Biologics, has a very negative P/E ratio of -84.40, amount in contrast with the average P/E of the market and companies from Korea, Health Care industry, and Pharmaceuticals and Biotechnology sector. This negative P/E of Samsung Biologics means the company is making a huge loss (really negative net profit), so it is a compulsory for the firm to change their decissions in order to solve the problem. More Samsung Biologics financial data can be accessed on the link.

Finally, you could compare Samsung Biologics P/E with other Pharmaceuticals and Biotechnology companies or firms from Korea.

Samsung Biologics price to earnings

Next companies

Samsung Card. Korea. Financials.
Samsung Electro-Mech. Korea. Industrials.
Samsung Electronics. Korea. Consumer Goods.
Samsung Eng. Korea. Industrials.
Samsung F & M Ins. Korea. Financials.
Samsung Fine Chem. Korea. Basic Materials.

Previous companies

Samsonite Internatio. Hong-Kong. Consumer Goods.
Sampo Oyi. Finland. Financials.
Salvatore Ferragamo. Italy. Consumer Goods. USA. Technology.
Saipem. Italy. Oil and Gas.
Sainsbury (J). UK. Consumer Services.

All rights reserved

 information advertisement legal

Dividends Ranking | Firm Report | Price to BookValue | Price to Cash-Flow | Price to Earnings | Return on Equity

Part of Enciclopedia Financiera Group

Disclaimer: Information on this site is only for informational purposes. Always consult a professional advisor before investing.